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Abstract 
Aims: Nucleolar morphometric features have a potential role in the assessment of 
aggressiveness of many cancers. However, the role of nucleoli in invasive breast cancer 
(IBC) is still unclear. This study aimed to investigate the optimal scoring method of 
nucleoli in IBC and their prognostic significance, and refine the grading of BC by 
incorporating the nucleolar score.  
Methods and results: Digital images acquired from hematoxylin and eosin (H&E) 
stained sections from a large IBC cohort were divided into training (n=400) and 
validation (n=1200) sets were used in this study. Four different assessment methods 
including 1) modified Helpap’s method, and counting prominent nucleoli (size ≥2.5µm) 
in 2) 10 field views (10 FVs), 3) 5 FVs and 4) 1 FV were evaluated in the training set to 
identify the optimal method associated with the best performance and significant 
prognostic value. The optimal method was applied to the validation set and to an 
external validation set the Cancer Genome Atlas (TCGA) data (n=743). Scoring 
prominent nucleoli in 5 FVs, showed the highest inter-observer concordance rate 
(intraclass correlation coefficient = 0.8) and significant association with breast cancer 
specific survival (BCSS) (p<0.0001).High nucleolar score was associated with younger 
age, larger tumor size and higher grade. Incorporating of nucleolar score in the 
Nottingham grade system showed higher significant association with survival than the 
conventional grade.  
Conclusions: Quantification of nucleolar prominence in 5 FVs is a cost-efficient and 
reproducible morphological feature that can predict IBC behaviour and can provide an 
alternative to pleomorphism to improve BC grading performance. 
Keywords: Nucleoli, invasive breast cancer, methods, prognosis  
INTRODUCTION 
Histological grade of invasive breast cancer (IBC), using the Nottingham grading system, 
is one of the strongest prognostic indices to guide management 1-3. Nuclear 
pleomorphism, together with tubule formation and mitotic count, are used to determine 
histological grade using light microscopy. However, the subjective nature of the grading 
system results in subsequent variation among pathologists and hence variation in 
patients’ management decisions 4. Amongst the three parameters of the Nottingham 
grading system, assessment of nuclear pleomorphism is considered the least 
reproducible component due to its subjective ill-defined scoring criteria, thus it shows 
the lowest level of inter-observer agreement 5. The agreement of assessing nuclear 
pleomorphism in IBC among expert breast pathologists ranges from 0.35 6 to 0.59 7 by 
Kappa statistics. 
Morphological changes in the nucleoli are considered as one of the first histopathological 
characteristics of malignant transformation, along with abnormal mitotic figures, 
thickened and irregular nuclear membrane and coarse chromatin 8. Malignant cells 
represent a variety of changes in nucleolar structure including nucleolar composition, 
size, number and chromatin texture. The nucleolar size and number correlate with the 
increase in the grade of malignancy 9. MacCarty et al described that the nucleolus could 
show much larger size in relative proportion to the size of the nucleus in malignant cells 
regardless of the type or origin of the neoplasm 10. Nevertheless, nucleolar size plays a 
central proportional role in the rate of cell proliferation, and its morphology is closely 
related to cancer growth 11-13. The major role of the nucleolus is synthesis of rRNA, 
processing and assembly of ribosomal subunits 14-16. Increased number and size of 
nucleoli indicates higher rate of ribosome biogenesis representing a major metabolic 
requisite for cell growth and proliferation 17, 18. These changes in the nucleolus is linked 
to growth factors and oncogene proteins which induce cell proliferation such as 
epidermal growth factor 19, insulin-like growth factor 20 and c-Myc 21.  
Prominent nucleoli were shown to be associated with poor outcome in various tumors 8, 
including BC 22. Quantitative nucleolar morphometry predicts metastasis and biochemical 
recurrence in prostate cancer 23. Furthermore, nucleolar size assessed by silver staining 
of argyophilic nucleolar organiser regions (AgNOR) was reported to be associated with 
poor clinical outcome of BC in several studies 8, 24, 25.  
However, nucleolar morphometric features are not widely assessed in IBC, due to lack of 
reliable assays that can be routinely implemented in a clinical setting. With the 
progressive deployment of digital platforms in reporting pathology laboratories, the 
assessment of subcellular details including nucleoli might become a feasible practice to 
improve BC grading performance and to capture useful prognostic value using artificial 
intelligence techniques or visual eyeballing method. Therefore, in this study we sought to 
investigate the optimal method of nucleoli evaluation using digitised images, in terms of 
reliability, reproducibility and prognostic significance, in large cohorts of BC. Also, the 
added value of nucleolar score to refine the performance of Nottingham grading system 
was assessed. 
MATERIALS AND METHODS 
Study Cohorts 
Nottingham Cohort 
This study was conducted on a large series (n=1600) of primary operable BC presented 
to Nottingham City Hospital, Nottingham, United Kingdom between 1999-2006. This is a 
well-characterised cohort with long term clinical follow-up (median 138 months, range 
0-216 months) and detailed clinico-pathological data including patient’s age at diagnosis, 
primary tumor histological grade, tumor size and histological tumor type, Nottingham 
Prognostic Index (NPI), molecular subtypes and outcome data. The latter includes breast 
cancer specific survival (BCSS), defined as time (in months) from the date of the 
primary surgery to the time of death from BC and distant metastasis free survival 
(DMFS), and defined as the time (in months) from the primary surgery until the first 
event of distant metastasis. 
For the purpose of this study, this cohort was divided into two-groups: the first 
sequential 400 cases (25%) of the cohort were used as a training set and the 
subsequent 1200 cases were used as a validation set. Supplementary table 1 
summarizes the Clinicopathological parameters of both sets. 
Freshly cut, 4 µm thick, full face sections for the Nottingham cohort were stained with 
Haematoxylin and Eosin (H&E), one section per case from the tumor block that showed 
the largest tumor burden defined by > 50% of the section area. H&E slides were 
scanned into high definition digital images through a high-resolution (0.19 µm/pixel) 
scanning using high throughput scanner (Pannoramic 250 Flash III, 3D-Histech, 
Budapest, Hungary), followed by viewing the slides using Case Viewer Software program 
(version 2.2.0.85, 3D-Histech, Budapest, Hungary) on full screen panel (size = 21inch, 
resolution = 1366×768). These tumors were graded using the digital images as 
previously described 26. 
External Validation Cohort 
In addition, digital H&E IBC images from The Cancer Genome Atlas (TCGA) 27 (n=743), 
have been used as further external validation set. These images were digitized at 40X 
objective magnification contains upward of 1010 pixels and has long term clinical follow-
up (10 years) .All the images were directly downloaded from cBioPortal website and 
viewed on case viewer for nucleolar score 28. 
Scoring of Nucleoli 
In this study, nucleoli were assessed using visual scoring of the digitised whole slide 
images according to the following four scoring methods:  
(1) Modified Helpap’s method 29, that was based on results related to prior work 30. This 
method stratified nucleoli into three scores based on their prominence. Nucleoli were 
assigned score 1 if no prominent nucleoli (i.e. inconspicuous), or single less prominent 
nucleoli that are difficult to see at 20x were observed. A nucleolar score 3 was assigned 
if prominent nucleoli, which were easily seen at 10x and were identified in at least 20% 
of the tumor 31 or dysmorphic/multiple nucleoli were present. Score 2 was assigned to 
those tumor with nucleoli not scored 1 or 3. 
For objectivity enhancement, nucleoli were also scored at 40x, and were stratified using 
the number of prominent nucleoli (defined as ≥ 2.5µm in size or easily seen at 10x) per 
defined number of field views (FVs) on the screen;  
(2) Counting in 10 FVs (equivalent to 1mm2 area) 
(3) 5 FVs (0.5mm2) and  
(4) 1 FV (0.1mm2).  
Counting was carried out within the nucleoli hotspot defined as area of conspicuous 
nucleoli observed by scanning the images at 10x. Examples of nucleolar score in 1FV are 
shown in Figure 1. The cases were scored based on the absolute number of prominent 
nucleoli and then cutoffs were applied to categorise the cases into 3 scores; 1, 2 and 3.  
To check the reliability and reproducibility of the nucleolar evaluation methods, the 
training set was scored using all aforementioned methods by four observers, where the 
first observer scored all the cases, while the others scored 25% of the training set. The 
optimal method for nucleolar score was determined based on the level of reproducibility 
in terms of inter-observer concordance and the association with outcome. 
The first validation set (n=1200 cases) was scored by two observers using the chosen 
method, where the first observer scored all the cases, while the other scored 50% of the 
cases to further assess the level of concordance of this method. Nucleolar score carried 
out by the first observer (KA) was considered in the final statistical analysis. For external 
validation of the optimal method chosen, digital images of scanned H&E full-face slides 
of the TCGA were scored by one observer. 
In previous study we graded the Nottingham cohort twice using whole slide images by 
one observer 32, and data on the concordance of grade and pleomorphism was used in 
this study. Moreover, incorporation of the nucleolar score in the Nottingham Grading 
System was attempted to assess the performance of the Nottingham grade with the 
addition of this score to the three components and or replacement of nuclear 
pleomorphism.  
Statistical analysis  
The optimal cut-off point of nucleoli count against BCSS was defined using X-tile 
bioinformatics software version 3.6.1 (School of Medicine, Yale University, New Haven, 
USA)33. Nucleoli were given three scores depending on these cut-off points 
(Supplementary Table 2). Also, new grade scores of Nottingham grading system were 
obtained using cut-off points of total scores against BCSS using X-tile. IBM-SPSS 
statistical software 24.0 (SPSS, Chicago, IL, USA) was used in statistical analysis. The 
degree of inter-observer agreement was assessed through intra-class correlation 
coefficient (ICC) for continuous data. Fleiss’ Kappa statistic was used to assess the 
concordance between more than two observers for categorical variables. Association 
between nucleoli count with different concordant and discordant cases was analyzed 
using Kruskal-Wallis test. Outcome analysis was assessed using Kaplan-Meier curves and 
the log-rank test. Cox proportional hazards multivariate regression modelling was used 
for the multivariate analysis. For all tests, p- values < 0.05 (two-tailed) were considered 
as statistically significant. 
RESULTS 
This study included two cohorts of IBC: 1) the Nottingham cohort (n=1600 cases) split 
into: a) a training set comprising 400 cases scored by four observers using four different 
scoring methods and b) a validation set (n=1200), which was scored by counting 
nucleoli in 5 FVs by two observers. 2) an external validation cohort; TCGA cohort (n= 
743) to assess the performance of the optimal scoring method.  
A) The training set: 
The highest degree of inter-observer agreement was observed in counting nucleoli in 5 
FVs (ICC = 0.782), whereas the least concordance was seen with the modified Helpap’s 
method (Fleiss’ Kappa value = 0.417). The concordance rate of nucleolar score using 
different methods between the four observers is summarized in Supplementary Table 3. 
The percentage of cases scored 3 using Modified Helpap’s method, and at 10, 5 and 1 FV 
were 17%, 16%, 17%, and 18%, respectively. Their association with BCSS, DMFS are 
summarized in Table 1.  
Higher nucleolar score showed significant association with BCSS (p=0.011, p=0.013, 
and p=0.024 for nucleolar score in 10, 5 and 1 FV, respectively) while modified Helpap’s 
method showed no association (p=0.195) Figure 2. A similar observation was seen with 
DMFS Supplementary Figure 1. 
B) The validation set: 
The nucleoli were assessed in the validation set using the 5 FVs method, where the 
concordance rate between the two observers was (ICC = 0.981). Nucleolar score in the 
validation set showed that 534 cases (45%) had score 1, 40% of cases had score 2 and 
15% of cases showed score 3. 
Association of nucleoli with other clinicopathological parameters: 
High nucleolar score was associated with parameters characteristic of aggressive tumor 
behavior including younger patient age, larger tumor size, higher tumor grade, stage 3, 
and poor Nottingham Prognostic Index (NPI). Only 10% of cases with nucleolar score 1 
were high grade lesions in comparison with 40% and 63% of nucleolar score 2 and score 
3, respectively (p<0.0001). Also, significant association was observed between nucleoli 
and number of positive axillary lymph nodes where 14% of cases with nucleolar score 3 
showed more than 3 positive lymph nodes compared with 10% and 5% of cases with 
nucleolar score 2 and 1, respectively (p<0.0001).  
Nucleolar score 3 tumors were more associated with oestrogen receptor negativity, 
progesterone receptor negativity and HER2 positivity (all p<0.0001). Significant 
associations were found between nucleolar score and histological subtypes of IBC where 
97% of nucleolar score 3 tumors were of no specific histological type (NST) (p<0.0001). 
The association between nucleolar scores and various clinicopathological parameters are 
summarized in Table 2. 
Association of nucleolar score with grade concordant and discordant cases: 
To assess the value of using nucleolar score in cases associated with low grade 
concordance (cases with borderline features for grade using the Nottingham grading 
system), nucleolar score was applied to the subgroups of IBC based on grade 
concordance 32. Significant association was observed between nucleolar score and grade 
concordant and discordant cases (p<0.0001). 13% of grade concordant cases (G2/2) 
had nucleolar score 3 compared to 29% of discordant cases (G2/3) nucleoli was score 3. 
On other hand, when we compared between nucleolar score 2 in (G2/2) & (G2/3), we 
found that this percentage is decreased from 50% to 44%. Also, it was illustrated in the 
bar chart (supplementary figure 2) that (G2/3) has higher nucleolar score than (G2/2). 
Association between nucleoli counting in 5 FVs and concordant and discordant cases are 
shown in Supplementary Figure 2.  
Outcome analysis: 
In the whole cohort, significant associations were observed between high nucleolar score 
and shorter BCSS and DMFS (Log-rank=33.32, p<0.0001 & Log-rank= 33.72, p<0.0001 
respectively) as shown in Figure 3. 
Multivariate Cox regression model adjusting for the standard prognostic 
clinicopathological parameters including patient age, tumor size, and nodal stage showed 
nucleolar score as an independent predictor of survival (Table 4).   
When the analysis was restricted to the most common type duct NST excluding special 
tumor types, incorporation of nucleolar score to the other grade components in Cox 
regression model showed that nucleoli was independent prognostic factor in survival 
prediction (hazard ratio=1.259, 95% confident interval= 1.03-1.53, p value=0.022) 
while pleomorphism was not significantly associated with outcome. Moreover, when 
pleomorphism was replaced with nucleolar score, the latter was independent predictor 
and showed more significant than nuclear pleomorphism (hazard ratio=0.004, 95% 
confident interval= 1.09-1.58, p value=0.004). Table 5 summarize the multivariate 
analysis results for various models used.  
Nucleoli and the Nottingham grading system: 
The incorporation of nucleolar score, as a replacement of nuclear pleomorphism, in the 
Nottingham grading system specially in NST cases Table 6 showed higher significant 
association with BCSS (Log-rank= 102, p=8.3× 10-23) than the normal grade (Log-
rank=96, p=1.6 × 10-21). In addition, when the nucleolar score was added to the 
existing grade components, it still showed higher significant association with survival 
than normal grade (Log-rank=104, p =2.8×10-23), (Figure 4). Groups with new grade 
scores are illustrated in Supplementary Table 4. 
A multivariate cox regression model including tumor size, nodal stage and tumor grade 
after replacing nuclear pleomorphism with nucleolar score or adding the nucleolar score 
as an additional feature, showed that those grades are independently predictive of 
survival (p= 8.2 × 10-13 & p= 6.1 × 10-13, respectively) better than the normal grade 
(p= 1.2 × 10-13) (Supplementary Table 5). 
Validation of nucleoli assessment in an external (TCGA) cohort: 
Nucleolar score using the optimal method in the TCGA data set showed that 354 cases 
(48%) were of score 1, whereas scores 2 and 3 comprised 41% and 11% of cases, 
respectively. High nucleolar score was significantly associated with poor 10-year overall 
survival (OS) (Log-rank 12.81, p = 0.002).  
Moreover, incorporation of nucleolar score in tumor grade using the Nottingham Scoring 
method for TCGA cases, which were assessed by one observer (L. Dalton), showed that 
incorporation of nucleolar score as an additional component to the grade had stronger 
association with OS (Log-rank= 13.5, p=0.001) than conventional grade (Log-rank = 
11.9, p=0.003) and also an a association was observed  after replacing pleomorphism 
with nucleolar score in the grading system (Log-rank = 10.9, p=0.004) Figure 5. 
DISCUSSION 
The nucleolus is considered as a mirror of the cellular metabolic activity. Prominent 
nucleolus is associated with a high translational potential and is considered as an 
indicator of the cells’ high demand for proteins (e.g. proto-oncogene proteins). 
Prominent nucleoli are an indication of cellular kinetics and cytobiochemical changes that 
occur in cancer cells 31. In carcinoma, the association of nucleolar morphometric changes 
with poor patient prognosis is noteworthy and there is an increasing evidence from 
independent data that suggests an active role of the nucleolus in tumorigenesis 15, 34, 35.  
However, there are currently no consensus histopathological guidelines to evaluate 
nucleoli in BC clinical practice. Previous studies assessing the prognostic significance of 
nucleoli in BC lacked objective criteria for scoring nucleoli, and did not identify optimal 
cut-off points for prognostic stratification 31. In the current study, nucleoli were assessed 
using a variety of scoring methods in a large cohort of invasive BC with long-term follow-
up data to determine the most reproducible assessment method whilst also providing 
prognostic value. The applicability of incorporating nucleolar score into the routine 
grading system was also assessed.  
Assessment of nucleoli in the training set demonstrated that counting nucleoli in 5 FVs 
(0.5mm2) using digitesd whole slide images was the optimal method. This inference was 
based on the following; firstly, nucleolar score in 5 FVs had the highest concordance rate 
between the observers. Secondly, this method highly represents nucleoli within the 
whole slide without the requirement to count nucleoli in wider areas which is time 
consuming. Counting in 10 FVs requires more than 100 prominent nucleoli to stratify the 
tumor. It was also more objective than the modified Helpap’s method 29. Lastly, nucleolar 
score in 5 FVs showed significant association with the patient outcome. 
In 5 FVs method, we defined the nucleoli as >= 2.5 µm or easily seen at 10x to provide 
a distinction of what was observed at the level of research versus what might be applied 
in clinical practice. We utilised an eyepiece reticle in which 2.5 microns was the breadth 
between two cross-hatches at 40x. It was apparent to the observers that 2.5 microns at 
40x via the reticle correlated with what was easily seen at 10x and therefore the 
eyepiece reticle was made redundant. We think that in daily clinical practice the 10x rule 
could be used based on our experimental observations at 2.5 microns.  
In addition, we followed the same method of counting mitotic figures in routine practice 
of grading by choosing field with enough degree of cellularity and we relied on hotspots. 
We chose the field for counting after scanning the whole tumour using low power at 10x 
to locate nucleoli hotspots. We used fixed number of areas (hotspots) to count the 
prominent nucleoli in all cases. Nucleoli were given three scores depending on cut-off 
point generated with X-tile against breast cancer specific survival (BCSS). 
The main disadvantage of the modified Helpap’s method is the lack of information on the 
number of field views or the number of cells with prominent nucleoli to be scored or 
even the size of nucleoli to be considered. Although we followed the method 
recommended by Donizy et al. 31 in melanoma, which used 20% of the tumor cells with 
prominent nucleoli, it was still more subjective than counting a defined number of 
FVs. This might also explain the discrepancies in high nucleolar scores between different 
methods as the modified Helpap’s method required >20% of the tumor cells with 
prominent nucleoli (i.e. thousands of cells), while in the other methods, fewer cells with 
prominent nucleoli were counted to consider a high score. 
High nucleoli count showed significant association with poor BCSS and shorter DMFS in 
both training and validation cohorts and also overall survival in the external validation 
cohort. Association between prominent nucleoli and poor prognosis has also been 
reported in melanoma 31 and prostatic cancer 23. 
Based on the association between nucleolar score with concordant and discordant cases, 
we can rely on the nucleolar score if the tumor is high or low grade. When we compared 
between concordant cases with discordant cases we found that precentage of nucleolar 
score 3 in (G2/3) was higher than (G2/2). The statistical significance here is related to 
these variations in percentages between groups and not to the absolute percentage. So, 
we concluded that the nucleolar score could provide an additional feature to determine 
the grade of these borderline cases. 
In our study, high nucleolar score showed higher association with NST than lobular and 
other special types which include invasive cribriform, invasive mucinous and tubular 
carcinoma. NST is the most common type of IBC that constitutes 40-75% of all 
mammary invasive carcinomas 36 and is associated with poor prognosis in comparison to 
other types 37. We therefore incorporated nucleolar score to the tumor grade in NST 
cases only. 
Despite the objective improvements that have been made to BC grading methods, any 
assessment of morphological characteristics inevitably retains a subjective element and 
is heavily dependent on the pre-analytical parameters. Nuclear pleomorphism indicates 
shape, chromatin distribution and size of nucleolus. Lack of clear definitions of this 
grading criterion, their multiplicity, and subjectivity 5, 38 of measurement resulting in poor 
reproducibility, are strong motivations to replace it with other more objective 
components. Also, nuclear pleomorphism showed the least concordance among grade 
components between pathologists in several studies 6, 7, 38, 39.  
Multivariate Cox regression model incorporating nucleolar score in 5 FVs with the 
Nottingham grade components including pleomorphism 40 in NST cases showed that 
nucleolar score was independent predictive factor of outcome. In addition, after removal 
of nuclear pleomorphism from the model’s co-variates, nucleolar score showed a high 
significant association than pleomorphism.  Therefore, nucleolar scores could be more 
predictive of outcome than pleomorphism. These findings support the hypothesis that 
nucleoli could be incorporated into grade, following our approach of quantitation and 
scoring, to provide a more objective measurement than using pleomorphism.  
When we replaced nuclear pleomorphism with nucleolar scores, it showed higher 
significant association with patient outcome than grade with pleomorphism. Also, when 
adding nucleolar score as an additional feature to the grade, it showed highly significant 
association with BCSS. These findings support our hypothesis that nucleolar score could 
be a promising parameter to be assessed to enhance the grading system.  
In conclusion, assessment of nucleoli in H&E stained full face invasive breast carcinoma 
sections in 5 FVs using whole slide images is a reproducible and practical method to 
predict tumor behavior and progression and also provides more evidence for the 
reproducibilty and reliability of using digitised images in clininal pratice. The use of whole 
slide images technology in nucleolar assessment also opens up opportunities for 
computer-assisted classification for easier determination of 2.5 microns with improved 
standraisation and reproducibility of evaluation for refinement of methodology by 
training deep learning models. Application of this method in routine practice would aid in 
risk-stratification of invasive BC for more individualized patient management. 
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Table (1): Association of nucleolar score as defined by the four methods used and 
patient outcome in terms of breast cancer specific survival (BCSS) and distant 
metastasis free survival (DMFS) in the training set.  
Methods
Nucleolar score 







Significant p values are in bold 
Table (2): Association between nucleolar scores in 5 field views (0.5mm2) and 
clinicopathological parameters in Nottingham cohort (n=1600). Nucleolar scores cut-off 



















Nucleoli scoring in 10 field 






9.1   
(0.011)
6.7   
(0.035)
Nucleoli scoring in 5 field 










Nucleoli count in 1 field 










Parameter Nucleolar score Chi- square 
(χ2) 
(p-value)







   ≤ 50 years 










  ≤ 2cm 









* Other special types include tubular, mucinous, cribriform, papillary, micropapillary 
Significant p values are in bold 
Table (3): Association between nucleolar scoring in 5 field views (0.5mm2) and 
concordant and discordant cases in the whole cohort (n=1600). Nucleolar score cut-offs 
were determined by X-tile. 
Tumour grade  
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Oestrogen receptor status  
   Positive  











   Positive  









HER2 receptor status  
   Positive  











  Good 













Lymph node positive (LN) 
  Negative   
  Positive 1-3 













No specific type (NST) 
Lobular 












Parameter Nucleolar score Chi- square 
(χ2) 
(p-value)
Score 1  Score 2 Score 3 















    Significant p values are in bold 
Table (4):  Multivariate Cox regression analysis results for predictors of Breast Cancer 
Specific Survival in Nottingham cohort. 
Significant p values are in bold 






























Parameters Hazard ratio 
(HR)




Nucleoli scoring 1.357 1.161 1.584 0.0001
Tumour size 1.561 1.222 1.994 0.0004
Stage 2.151 1.845 2.508 <0.0001
Patient age 1.217 0.956 1.548 0.11
Table (5): Multivariate Cox regression analysis of the components of grade as predictors 
of Breast Cancer Specific Survival, with and without inclusion of nucleolar scores. 










Nuclear pleomorphism 1.294 1.016 1.648 0.037
Mitosis 1.473 1.239 1.751 <0.0001
Tubule formation 2.178 1.446 3.281 <0.001 
(B) 
Nuclear pleomorphism 1.166 0.902 1.508 0.241
Mitosis 1.454 1.223 1.729 <0.0001
Tubule formation 2.125 1.411 3.201 <0.001
Nucleoli scoring 1.259 1.034 1.533 0.022
(C) 
Nucleoli scoring 1.314 1.093 1.580 0.004
Mitosis 1.525 1.305 1.781 <0.0001
Tubule formation 2.249 1.510 3.349     <0.0001 
Table (6):  Frequency of tumour grade and their association with outcome in terms of 
BCSS after adding nucleolar scoring to the grading system in no specific type (NST) 
cases (n=1198) (log-rank test). 
Significant p values are in bold 
FIGURE LEGENDS 
Figure (1): Examples of nucleolar scores 1, 2 and 3 in 1 field view (1FV) (yellow arrows 
indicate prominent nucleoli considered in counting), haematoxylin & eosin at x40. 
Parameter Tumour grade 
Number of cases (%)
Survival 
Log-rank 
(p-value)  Grade 1 Grade 2 Grade 3
Tumour Grade 337 (28) 523 (44) 338 (28) 96 
(1.6 × 10 
-21)
Grade after replacing nuclear 
pleomorphism score with 
nucleoli score
199 (17) 602 (50) 397 (33) 102 
(8.3 × 10 
-23)
Grade after adding nucleoli 
score to the other three 
components of the grade
262 (22) 574 (48) 362 (30) 104 
(2.8 × 10 
-23)
Figure (2): Kaplan-Meier survival plots showing association of nucleolar scores using 
the four different assessment methods with breast cancer specific survival (BCSS) in 
training set. A) Nucleolar scoring using Modified Helpap’s method, B) Nucleolar scoring in 
10 field views (1mm2), C) Nucleolar scoring in 5 field views (0.5mm2), and D) Nucleolar 
scoring in one field view  (0.1mm2).  
Figure (3): Kaplan-Meier plots showing association of nucleolar scoring in 5 field views 
(0.5mm2) with (A) Breast cancer specific survival (BCSS) and (B) Distant metastasis free 
survival (DMFS) in Nottingham cohort. 
Figure (4): Kaplan-Meier survival plots showing breast cancer specific survival (BCSS) 
of (A) Nottingham tumor grade, (B) Nottingham grade after replacing nuclear 
pleomorphism with nucleolar score, (C) Nottingham grade after adding nucleolar score to 
its components in no-specific type (NST) cases. 
Figure (5): Kaplan-Meier survival plot showing overall survival (OS) of (A) Nucleolar 
scoring in 5 field views (B) Tumor grade (C) Tumor grade after replacing nuclear 
pleomorphism with nucleolar score, (D) Tumor grade after adding nucleolar score to its 







Supplementary Table (1): Clinicopathological characteristics of the cases in both training 
(n=400) and validation sets (n=1200) of the study cohort.  
Parameter Training set  Number of cases (%)
Validation set  
Number of cases (%)
Patient Age 
   ≤ 50 years 






  ≤ 2cm 





Tumour grade  
  1 









  1 








Lymph node status (LN) 
  Negative   
  Positive 1-3 







Oestrogen receptor status  
   Positive  





Progesterone receptor status  
   Positive  




HER2 receptor status  
   Positive  





Nottingham prognostic index 
(NPI) 
  Good 






















Supplementary Table (2): Cut-off points of nucleoli count as generated by the X-tile 
Bioinformatics software based on the association with breast cancer specific survival (BCSS).  
Supplementary Table (3): Nucleolar scoring inter- observer concordance results in the 
training set (n=400). 
a Preformed using Intra-class correlation coefficient.  
*Performed using Fleiss’ Kappa test between four observers. 
Parameter
Definitions of Nucleoli Count  
Score 1 Score 2 Score 3 
Nucleoli count in 10 field views (1mm2) (at 40x) 0-4 5-101 > 101
Nucleoli count in 5 field views (0.5mm2)(at 40x) 0-2 3-50 > 50
Nucleoli count in 1 field view (0.1mm2) (at 40x) 0 1-9 > 9
Parameter 95% confident interval (CI)  Inter-observer 
reliability
Lower Upper
Modified Helpap’s method 0.359 0.474 0.417*
Nucleoli count in 10 field views 
(1mm2) (at 40x)
0.612 0.786 0.712 a
Nucleoli count in 5 field views 
(0.5mm2) (at 40x)
0.703 0.844 0.782 a
Nucleoli count in 1 field view 
(0.1mm2) (at 40x)
0.692 0.839 0.774 a
Supplementary Table (4): Incorporation of nucleolar scores into the Nottingham Grading 
System. Cut-off points of grade scores were generated by X-tile software based on association 
with breast cancer specific survival (BCSS) in no specific type (NST) cases.  
     
Supplementary Table (5): Results of multivariate Cox regression analysis in no-specific type 
(NST) cases (n=1198). 
Groups Score Equivalent Grade
Group (1) Grade after replacing nuclear 
pleomorphism score with nucleolar score
Total score 3, 4  





Group (2) Grade after adding nucleolar 
score to the other three components of the 
grade
Total score 4, 5 ,6 














Grade 2.019 1.677 2.432 1.2 ×10-13
Tumour size 1.591 1.222 2.070 0.001
Stage 2.037 1.722 2.410 1.1 ×10-16
  (B)
Grade after replacing 
nuclear pleomorphism score 
with nucleolar score
2.182 1.762 2.702 8.2 ×10-13
Tumour Size 1.493 1.141 1.952 0.003
Stage 2.010 1.697 2.381 6.1 ×10-16
Significant p values are in bold 
  (C)
Grade after adding nucleolar 
score to the other three 
components of the grade
2.083 1.706 2.544 6.1×10-13
Tumour size 1.518 1.161 1.983 0.002
Stage 2.027 1.712 2.400 2.6 ×10-16
Supplementary figures 
Supplementary Figure (1): Kaplan–Meier survival plot showing association of the four 
different scoring methods of nucleoli with distant metastasis free survival (DMFS) in training 
set. These show nucleolar scoring A) using Modified Helpap’ method, B) in 10 field views 
(1mm2), C) in 5 field views (0.5mm2), and D) in one field view method (0.1mm2). 
 
Supplementary Figure (2): Bar charts showing association of nucleoli counting in 5 field 
views (0.5mm2) and (A) Grade concord ant cases (B) Grade high discordant cases (C) Grade 
low discordant cases in Nottingham cohort. 

